Research programme: anti-proliferative therapeutics - DiscoveryBioMed

Drug Profile

Research programme: anti-proliferative therapeutics - DiscoveryBioMed

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DiscoveryBioMed
  • Developer DiscoveryBioMed; University of Maryland School of Medicine
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Autosomal dominant polycystic kidney disease

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Autosomal-dominant-polycystic-kidney-disease in USA
  • 08 Jun 2016 DiscoveryBioMed and Mayo Clinic collaborate to co-develop for ADPKD
  • 08 Jun 2016 DiscoveryBioMed and University of Kansas Medical Center collaborate to co-develop for ADPKD
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top